Biotech Values

[oc631]

So VRUS has all promising interferon-sparing combos: all nukes, nuke + NS5A, and now nuke+PI

BMY and Tibotec are two of the finest companies in the space so I'm quite happy about the way things are developing. Large pharma scrambling to test their lead compounds with a mid-cap like VRUS certainly is an exception to the industry rule. I have the utmost confidence the CEO will use all the leverage he has in partnering PSI-7977 on very favorable terms for shareholders. If all goes well VRUS might keep the GT2/GT3 market for themselves and enjoy the first to market warehousing effect now underway with VRTX/MRK in GT1.

Care to comment on the chances of an early filing for PSI-7977/PegRiba in the underserved GT2/GT3 patient group?